Neprilysin has a monoclonal antibody, which is used to detect the protein. It is produced in the laboratory using HEK T cells transfected with mammalian expression vectors and then selected by G418. After that, culture medium and total cell extracts are used for the production of recombinant proteins. In addition to this, the anti-Neprilysin antibody is used to detect neprilysin through the membrane.
Neprilysin is an integral membrane-bound metallopeptidase with a broad range of physiological functions. It is involved in the proteolytic processes in the kidney, regulates the blood, and plays a role in the development of a foetus. In addition to its beneficial role in human health, it has been implicated in the pathogenesis of COVID-19. Although the exact role of this protein is still unclear, it is essential in a wide range of diseases.
The anti-neprilysin market is estimated to be valued at US$ 1,109.25 million in 2021 and is expected to exhibit a CAGR of 4.6% during the forecast period (2022-2028).
Get Free Sample PDF Copy (Including Full TOC, List of Tables & Figures, Chart) @
The pandemic of COVID-19 has significantly augmented demand for several drugs. The spread of coronavirus is also negatively impacting the sales of companies, whose product demand highly depend on selective disease treatments such as anti-neprilysin, which is majorly used for treatment of heart diseases. Furthermore, cardiovascular disease patients are highly at risk of being affected by COVID-19 infection due to fragile heart conditions. The COVID-19 infects the lungs, drop blood oxygen levels at first and secondly, the inflammatory effects of the virus itself will cause the blood pressure to drop. In such cases, the heart must beat faster and harder to supply oxygen to major organs due to which the survival rates of individuals with ailing heart conditions become very less even with proper medications.
Increasing prevalence of hypertension, Alzheimer’s disease, stroke, atrial fibrillation, and renal diseases is driving anti-neprilysin treatment market growth. Thus, increasing prevalence of such diseases is expected to boost the anti-neprilysin market growth over the forecast period. For instance, according to the World Health Organization (WHO) report of September 2019, around 1.13 billion people worldwide suffered from hypertension, most living in low- and middle-income countries in 2019. Moreover, rising prevalence of hypertension increases the risk of heart attack, stroke, and kidney damage, as well as other health problems.
Furthermore, the anti-neprilysin market is expected to witness significant growth in the near future, due to growing product approvals by regulatory bodies. For instance, in February 2015, Novartis International AG announced that the U.S. Food and Drug Administration (FDA) granted priority review for LCZ696, an investigational medicine for the treatment of heart failure with reduced ejection fraction (HFrEF). The designation is intended to accelerate the review of therapies that offer a significant improvement in the safety or effectiveness of the treatment, prevention or diagnosis of a serious condition.
Anti-Neprilysin Market – Restraints
On the other hand, frequent drug recalls is expected to hinder the anti-neprilysin market growth. For instance, in July 2018, Novartis issued a voluntary recall of Entresto Hospital Unit Dose (HUD) tablets. This recall was issued, as the packaging of these products were not child-resistant, which could pose a risk of harm if the tablets are swallowed by children.
Request PDF Brochure with Latest Insights @
North America accounted for the largest share in the anti-neprilysin market in 2019, due to increasing agreements between companies in the region. For instance, in February 2016, Cigna Corporation and Aetna Inc. entered into an outcome-based studies agreement with the pharmaceutical company Novartis for the drug Entresto, which was approved by the U.S. Food and Drug Administration for the treatment of heart failure with reduced ejection fraction. In this agreement, Cigna’s pharmacists and nurses are involved in providing focused clinical care, which includes monitoring a customer’s medication adherence, side effects, and drug interactions, reviewing lab values, and collaborating with customers’ physicians when adjustments are needed.
Furthermore, the growing number of clinical trials of anti-neprilysin drugs are projected to accelerate the anti-neprilysin market growth in the near future. For instance, in June 2017, Pharmaleads, a France-based pharmaceutical company, announced positive results in a first Phase I trial for its DENKI peptide PL265 to treat chronic neuropathic pain. Moreover, the biotech company announced that its second clinical stage peptide, PL265, has successfully cleared a Phase I single-ascending dose (SAD) trial, allowing the company to move its compound towards the next stage of clinical development.
Key players operating in the anti-neprilysin market include Bioprojet SCR, Novartis International AG, Pharmaleads SA, Theravance Biopharma Inc., Cipla Limited, and Oceanic Pharmachem Pvt. Ltd.
Reasons to buy this Anti-Neprilysin Market Report
◘ Save time carrying out entry-level research by identifying the size, growth, and leading players in the emerging Anti-Neprilysin Market
◘ Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the emerging Anti-Neprilysin Market
◘ Leading company profiles reveal details of key Anti-Neprilysin Market players emerging five operations and financial performance
◘ Add weight to presentations and pitches by understanding the future growth prospects of the emerging Anti-Neprilysin Market with five year historical forecasts
◘ Compares data from North America, South America, Asia Pacific Europe and Middle East Africa, alongside individual chapters on each region
The next part also sheds light on the gap between supply and consumption. Apart from the mentioned information, growth rate of Anti-Neprilysin Market in 2028 is also explained. Additionally, type wise and application wise consumption tables and figures of Anti-Neprilysin Market are also given.
𝐁𝐮𝐲 𝐓𝐡𝐢𝐬 𝐂𝐨𝐦𝐩𝐥𝐞𝐭𝐞 𝐁𝐮𝐬𝐢𝐧𝐞𝐬𝐬 𝐑𝐞𝐩𝐨𝐫𝐭 𝐖𝐢𝐭𝐡 𝐅𝐥𝐚𝐭 𝐔𝐒𝐃 𝟐𝟎𝟎𝟎 𝐎𝐟𝐟 @
Table of Content
Chapter 1 Industry Overview
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Anti-Neprilysin Market Size Analysis from 2022 to 2028
11.6 COVID-19 Outbreak: Anti-Neprilysin Industry Impact
Chapter 2 Global Anti-Neprilysin Competition by Types, Applications, and Top Regions and Countries
2.1 Global Anti-Neprilysin (Volume and Value) by Type
2.3 Global Anti-Neprilysin (Volume and Value) by Regions
Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis
Chapter 4 Global Anti-Neprilysin Sales, Consumption, Export, Import by Regions
Chapter 5 North America Anti-Neprilysin Market Analysis
Chapter 6 East Asia Anti-Neprilysin Market Analysis
Chapter 7 Europe Anti-Neprilysin Market Analysis
Chapter 8 South Asia Anti-Neprilysin Market Analysis
Chapter 9 Southeast Asia Anti-Neprilysin Market Analysis
Chapter 10 Middle East Anti-Neprilysin Market Analysis
Chapter 11 Africa Anti-Neprilysin Market Analysis
Chapter 12 Oceania Anti-Neprilysin Market Analysis
Chapter 13 South America Anti-Neprilysin Market Analysis
Chapter 14 Company Profiles and Key Figures in Anti-Neprilysin Business
Chapter 15 Global Anti-Neprilysin Market Forecast (2022-2028)
Chapter 16 Conclusions
About Coherent Market Insights
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027